Modeling the impact of CDK4 / 6 inhibitors on reducing cancer mortality

Modeling the impact of CDK4 / 6 inhibitors on reducing cancer mortality

Background. Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors (abemaciclib, palbociclib, ribociclib) plus aromatase inhibitors (AI) are the modern standard-of-care of the first-line treatment of hormone-dependent (HR+) HER2-negative (HER2–) advanced breast cancer (ABC).Aim. To evaluate the effects of...

Full description

Saved in:

Bibliographic Details
Main Authors:	N. A. Avxentyev, E. V. Bilan, A. Yu. Goryainova, Yu. V. Makarova, R. A. Murashko, A. V. Sobolev, S. V. Sharov, D. Yu. Yukalchuk
Format:	Article
Language:	Russian
Published:	ABV-press 2025-05-01
Series:	Опухоли женской репродуктивной системы
Subjects:	breast cancer palbociclib ribociclib abemaciclib overall survival cancer mortality
Online Access:	https://ojrs.abvpress.ru/ojrs/article/view/1348
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Safety and quality of life of CDK4/6 inhibitors therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a multicenter cross-sectional survey in China
by: Benlong Yang, et al.
Published: (2025-05-01)

PRACTICAL ASPECTS OF ADMINISTERING CYCLIN-DEPENDENT KINASES INHIBITORS: EFFICACY AND TOLERABILITY
by: E. V. Artamonova
Published: (2018-04-01)

Effectiveness of cyclin-dependent kinase 4 and 6 inhibitors for the treatment of hormonesensitive HER2-negative metastatic breast cancer in first-line therapy: A systematic literature review
by: N. A. Avxentyev, et al.
Published: (2024-05-01)

A meta-analysis and systematic review of different cyclin-dependent kinase 4/6 inhibitors in breast cancer
by: Jialin Zhang, et al.
Published: (2025-03-01)

Patterns of treatment and outcomes of patients with metastatic HER2-low breast cancer treated with CDK4/6 inhibitors and hormone therapy
by: Federico Sottotetti, et al.
Published: (2025-05-01)

Selective cyclin-dependent kinase 4/6 inhibitors as anticancer drugs: Moving beyond hormone receptor-positive breast cancer
by: Tamojit Chaudhuri, et al.
Published: (2019-01-01)

Investigation of ribociclib, abemaciclib and palbociclib resistance in ER+ breast cancer cells reveal potential therapeutic opportunities
by: Mashael Algethami, et al.
Published: (2025-08-01)

The ICEDORA study: clinical and demographic characteristics and treatment regimens of patients with HR+ HER2- locally advanced or metastatic breast cancer receiving CDK4/6 inhibitors in real clinical practice
by: I. E. Khatkov, et al.
Published: (2025-07-01)

A rational approach to dose reduction of CDK4/6 inhibitors in the treatment of patients with advanced breast cancer: A narrative Review
by: I. N. Dyakov, et al.
Published: (2025-07-01)

Factors Affecting the Survival of Metastatic Breast Cancer Patients Treated with CDK 4/6 Inhibitors
by: Zehra Sucuoğlu İşleyen, et al.
Published: (2025-07-01)

Thymidine kinase 1 concentration and activity in metastatic breast cancer under CDK4/6 inhibitor therapy
by: Stefanos Ioannis Moukas, et al.
Published: (2025-03-01)

Pharmacoeconomic analysis of using cyclin-dependent kinase 4 and 6 inhibitors in the first line treatment of HR-positive HER2-negative advanced breast cancer
by: N. A. Avxentyev, et al.
Published: (2020-02-01)

Development of CDK4/6 Inhibitors in Gastrointestinal Cancers: Biomarkers to Move Forward
by: Ioannis A. Voutsadakis
Published: (2025-06-01)

PHARMACOECONOMIC EVALUATION OF RIBOCICLIB FOR THE FIRST-LINE TREATMENT OF HR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER
by: N. A. Avksentyev, et al.
Published: (2018-08-01)

A Comparison of the Efficacy and Safety of Denosumab and Zoledronic Acid in Patients with Bone Metastatic Breast Cancer Receiving CDK4/6 Inhibitor Therapy
by: İrem Öner, et al.
Published: (2025-02-01)

Monitoring the Response of Cyclin-Dependent Kinase 4/6 Inhibitors with Mean Corpuscular Volume
by: Bediz Kurt İnci, et al.
Published: (2024-09-01)

Estimating long-term overall survival with olaparib as maintenance therapy in patients with newly diagnosed advanced ovarian cancer with BRCA mutations
by: N. A. Avxentyev, et al.
Published: (2021-10-01)

Drug repurposing of cyclin-dependent kinase inhibitors for neutrophilic acute respiratory distress syndrome and psoriasis
by: Shun-Hua Chen, et al.
Published: (2025-06-01)

Escalation and De-Escalation Strategies for Endocrine Therapy in Early-Stage Breast Cancer
by: Al-Batsh T, et al.
Published: (2025-03-01)

A comparative analysis of Palbociclib and Ribociclib in metastatic hormone receptor-positive, HER2-negative breast cancer: a prospective mid term follow-Up study from an Indian cohort
by: Nihanthy D. Sreenath, et al.
Published: (2025-08-01)

Modeling the impact of using trastuzumab deruxtecan in patients with breast cancer on reducing cancer mortality in Russia
by: N. A. Avxentyev, et al.
Published: (2024-07-01)

The Effect of Proton Pump Inhibitors on Metastatic Breast Cancer in Patients Treated with CDK4/6i
by: Mohamed Khalifa, et al.
Published: (2025-04-01)

Real-world effectiveness of palbociclib in HR+/HER2- metastatic breast cancer: a literature review
by: Emilie Adrian Christiansen, et al.
Published: (2024-12-01)

Overall Survival With Palbociclib and Aromatase Inhibitor Versus Aromatase Inhibitor Alone in Older Patients With HR+/HER2− Metastatic Breast Cancer
by: Adam M. Brufsky, et al.
Published: (2025-04-01)

Escalation of adjuvant endocrine therapy for early hormone-dependent HER2-negative breast cancer: to whom, when and why?
by: I. V. Kolyadina
Published: (2024-05-01)

Ribociclib-induced phototoxicity - the era of new drugs and new toxicities
by: Bobić Simonida, et al.
Published: (2024-01-01)

CDK4/6 inhibitors in the treatment of metastatic breast cancer. Choosing optimal therapy for estrogen-receptor-positive HER2-negative metastatic breast cancer: analysis of doctors’ preferences (“Prometheus”) in Russia – first results of the survey
by: E. V. Artamonova, et al.
Published: (2021-01-01)

The influence of some clinical and morphological prognosis factors on the 5-year survival of patients with stage I cervical cancer
by: E. V. Makarova, et al.
Published: (2019-12-01)

An immunological mechanism of resistance to CDK4/6 inhibitors in HR+ breast cancer
by: Claudia Galassi, et al.
Published: (2025-12-01)

PALBOCICLIB IN COMBINATION WITH HORMONE THERAPY FOR LUMINAL HER2-NEGATIVE METASTATIC BREAST CANCER: NEW HIGHLY EFFECTIVE STRATEGY OF DRUG TREATMENT
by: E. V. Artamonova
Published: (2017-09-01)

Abemaciclib treatment patterns and outcome in HR+/HER2- locally advanced or metastatic breast cancer: a real-world study from Kuwait and Lebanon
by: Anwar Al Nouri, et al.
Published: (2025-06-01)

A Vitiligo-like Cutaneous Reaction Induced by Ribociclib in Advanced Breast Cancer: An Unusual Case Report from Colombia
by: John Fernando Montenegro, et al.
Published: (2025-05-01)

JNK pathway suppression mediates insensitivity to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer
by: Sarah Alexandrou, et al.
Published: (2025-08-01)

Letrozole and palbociclib in advanced breast cancer: Outcome from cancer institute, Chennai
by: Vijay Gnanaguru, et al.
Published: (2020-01-01)

Impact of HNF4α disrupted expression on hepatocellular carcinoma cells sensitivity to oncogenic pathways inhibitors
by: A. S. Makarova, et al.
Published: (2017-10-01)

EXPRESSION OF CANCER-TESTIS GENES PRAME, NY-ESO1, GAGE1, MAGE A3, MAGE A6, MAGE A12, SSX1, SLLP1, PASD1 IN PATIENTS WITH MULTIPLE MYELOMA, THEIR INFLUENCE ON OVERALL SURVIVAL AND RELAPSE RATE
by: A. A. Solodovnik, et al.
Published: (2018-07-01)

CDK4/6 inhibition mitigates stem cell damage in a novel model for taxane‐induced alopecia
by: Talveen S Purba, et al.
Published: (2019-09-01)

Mutations of the PIK3CA gene in patients with breast cancer in the Krasnoyarsk region
by: A. V. Zyuzyukina, et al.
Published: (2024-07-01)

Impact of age and comorbidities on real-world outcomes in advanced breast cancer patients treated with palbociclib in first line: a nation-wide Danish retrospective study
by: Alan Celik, et al.
Published: (2025-06-01)

Comparative long-term outcomes of first-line CDK4/6 inhibitors plus endocrine therapy versus endocrine therapy in patients with HR+/HER2-metastatic or advanced breast cancer: a meta-analysis
by: Xiaojian Wang, et al.
Published: (2025-07-01)